If you had been weighing Aurobindo Pharma’s push into complex generics and biosimilars against worries about US and European pricing pressure at the start of 2026, the past 11 months have given that debate teeth. Holding Aurobindo Pharma from the start of the year would have returned 52.1%, including dividends. If you were setting that position on 1 January 2026, how would you have balanced long-term biosimilar potential against the risk of margin squeeze in its core markets?
Aurobindo Pharma has already moved. See which of 195 high quality undervalued stocks still trade below our estimates.
The Two Stories Investors Had To Choose Between On Aurobindo Pharma
The shares cost ₹1,193 at the start of the period, so any decision on Aurobindo Pharma came down to which story about its future you trusted more.
The bullish narrative saw that price against a fair value of ₹1,930. That level was implied by assumptions built on complex generics and biosimilars driving stronger margins through backward integration, new plants, and higher margin launches by around FY 2027.
The bearish view pointed to a fair value of ₹730, again an implied number. It focused on US and European pricing pressure, higher compliance and environmental costs, and the risk that progress in complex generics would lag rising competition.
What The Results Changed For The Aurobindo Pharma Debate
The settlement that keeps Aurobindo Pharma’s NEXLETOL and NEXLIZET generics out of the US until April 2040 took some optionality away from the complex pipeline, which leaned against the bullish case. Quarterly numbers pulled the other way. Revenue moved from ₹82,857m to ₹102,632.9m, net income rose, and net margin lifted from 10.2% to 11.0%. The evidence cut both ways.
The lesson is simple. When a thesis hangs on richer products, track both margin trends and concrete product rights or delays. Then test each forecast against those filings.
What You Are Paying For In Aurobindo Pharma After A 52% Run
Aurobindo Pharma now trades at ₹1,807 after a 52.1% gain from the start of the year. The bearish analyst Narrative on Simply Wall St places its Fair Value below that level and argues the current tag already bakes in strong execution in higher value products.
The Narrative’s distinctive angle is simple. You need to ask whether complex generics, biosimilars and backward integration can outpace rising input and compliance costs that threaten to trap profitability near current levels.
"Although Aurobindo Pharma points to complex generics, injectables and biosimilars as future margin drivers, management has already flagged input costs such as solvents rising by around 2.5 to 2.7 times in early 2026. This can blunt the intended uplift from higher value launches and leave gross margin and EBITDA margin below what current expectations imply if this inflation persists or spreads to other raw materials."
That disagreement has a full argument behind it. → Uncover the lower Fair Value this Narrative argues for
One Step Beyond Aurobindo Pharma
Aurobindo Pharma keeps pointing you toward richer drug categories and sharper science. The next question is what supports those therapies across wider disease areas.
Think about complex treatments that still hinge on fresh medicines in cancer, heart health or infectious disease. Another global manufacturer is working on that same demand from a different angle.
This group leans on a broad human health pipeline backed by deeper research spending. It also runs a sizeable animal health arm, connected to food and pets.
As more attention goes to tougher conditions and longer lives, that mix matters. You might find the way it pursues new therapies worth a closer look.
That argument has a Narrative and a number behind it. → See the company one Narrative values 26% above its price
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com